Hematologic Malignancies Treatment Market

Global Hematologic Malignancies Treatment Market is valued at US$ 53.51 Billion in 2022 and expected to reach US$ 104.94 Billion by 2029 with a CAGR of 10.1% over the forecast period.

Global Hematologic Malignancies Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Rising incidences of blood cancer, increasing approvals of new drugs for the treatment and growing research & development activities are driving the growth of Global Hematologic Malignancies Treatment Market.

Scope of Global Hematologic Malignancies Treatment Market Report-

Hematological malignancy is a kind of cancer that influences the blood, bone marrow, and lymph hubs. They incorporate a few types of leukemia, myeloma, and lymphoma. Because therapies for blood cancer have vastly improved over recent many years, many kinds of blood cancers are presently profoundly treatable.

Hematological malignancy treatment has revolutionized cancer treatment by essentially further developing patient endurance both in solid tumors and hematologic malignancies. Hematological malignancies, like leukemia and lymphoma, afflict millions of kids and adults consistently, and are frequently dangerous. Bone marrow transplantation is a well recognized treatment for these diseases, accomplishing cure by substitution of sick blood progenitor cells with healthy stem cells. Recent technological advances have expanded the adequacy of immunotherapy prompting its more extensive application in different treatment settings.

The Covid-19 pandemic had a negative impact on the global hematologic malignancies treatment market. During Coronavirus pandemic, there were reduced research and development activities for the drugs utilized in hematologic malignancies treatment. The diagnostic facilities of clinical medication and pathology research facilities have been directly or indirectly impacted by the pandemic. The research & development activities for the medications to treat coronavirus contamination were on priority by vital participants in market. A major consequence of the Covid-19 pandemic has been on clinical trials restrictions for reducing the coronavirus infection. In certain centers, chemotherapy might need to be postponed or deferred if the patient tests positive for SARS-CoV-2 or because of a lack of isolation beds as well as blood products.

The global hematologic malignancies treatment market is segmented on the basis of condition, therapy, end-user, and region & country level. Based on the condition, the global hematologic malignancies treatment market is classified into lymphoma, leukemia, and myeloma. Based on the therapy, the market is classified into immunotherapy, chemotherapy, targeted therapy and others. Based on the end-user, the global hematologic malignancies treatment is classified into medical stores, hospital pharmacies and e-commerce platform.

The regions covered in global hematologic malignancies treatment market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global hematologic malignancies treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players for Global Hematologic Malignancies Treatment Report-

Some major key players in the global hematologic malignancies treatment market report cover prominent players like

• AbbVie Inc
• GlaxoSmithKline plc
• Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Johnson & Johnson Services  
• Bio-Rad Laboratories  
• Sanofi
• Takeda Pharmaceutical Company Limited
• others

Global Hematologic Malignancies Treatment Market Segmentation:-

By Condition: 

• Lymphoma 
• Leukemia 
• Myeloma 

By Therapy: 

• Immunotherapy 
• Chemotherapy 
• Targeted Therapy 
• Others 

By End-User: 

• Medical Stores 
• Hospital Pharmacies 
• E-Commerce Platform 

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Rising Incidences of Blood Cancer, Increasing Approvals of New Drugs for the Treatment and Growing Research & Development Activities are Driving the Market Growth

One of the major factors driving the growth of the global hematologic malignancies treatment market is the rising incidences of blood cancer. A hematologic malignancy, likewise called blood cancer, starts in blood-framing tissue, like the bone marrow, or in the cells of the immune system. Hematological disease is the fifth-most common kind of cancer on the planet and second-most driving reason for deaths. Hence, growing incidences of blood cancer drives the global myelodysplastic syndromes treatment market over the forecast period.

For example; according to the article published on Hindustan Times, there are around 1.24 million blood cancer cases that happen overall every year, representing about 6% of all cancer cases. In addition, another major factor for the growth of the global hematologic malignancies treatment market is due to increasing approvals of new drugs for the treatment. As early diagnoses and treatment is very important in hematologic malignancies.

Hence many government & private organizations get approval for development of hematologic malignancies treatment. For instance, as per the news published on April 19^th, 2022, Kite received U.S. FDA approval of new state-of-the-art CAR T-Cell therapy producing facility in Frederick, Maryland. The site will create Kite's FDA approved CAR T-cell treatment used to treat blood cancer.

Furthermore, the growing research & development activities also drive the global hematologic malignancies treatment market. For example; in May 2021, Tokyo-based Chugai Pharmaceutical Co. Ltd declared the launch of an anticancer specialist/antimicrotubule restricting anti-CD79b monoclonal immunizer called Polivy intravenous implantation 30 mg and 140 mg that can be utilized for the therapy of relapsed or refractory (R/R) diffuse huge B-cell lymphoma (DLBCL).

However, the high cost of medication include in the treatment may hamper the global hematologic malignancies treatment market growth. In spite of that, growing investments in cancer research provide various opportunities for the further growth of the global hematologic malignancies treatment market.

North America is Expected to Dominate the Global Hematologic Malignancies Treatment Market

North America is expected to dominate the global hematologic malignancies treatment market due to the growing prevalence of blood cancer, rising research & development activities and presence of key players in this region. There are approximately in every three minutes, one individual in the U.S. is determined to have leukemia, lymphoma or myeloma. Hence, rising blood cancer drives the global hematologic malignancies treatment market over the forecast period.

For example; according to the Leukemia & Lymphoma Society (LLS), an expected joined total of 186,400 individuals in the US are supposed to be determined to have leukemia, lymphoma or myeloma and about 57,750 individuals died due to leukemia, lymphoma or myeloma, in 2021.

Also, increasing research & development for developing treatment drive the global hematologic malignancies treatment market in this region. For instance; in February 2021, TG Therapeutics Inc. gotten the US FDA sped up approval for its UKONIQ (umbralisib), an oral, once-day to day inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of grown-up patients with relapsed or refractory marginal zone lymphoma (MZL) and grown-up patients with marginal follicular lymphoma (FL).

The Asia Pacific is anticipated to grow faster in the global hematologic malignancies treatment market within the forecast period due to increasing awareness about early diagnosis of blood-related cancer, rising healthcare expenditure and growing government support in the region. The rising health expenditure in the region, and support drives taken by government to spread awareness among individuals are assessed to help the development of the hematologic malignancies therapeutics market in the region.

News-

FDA Approved Treatment for Rare Blood Disease

On November 12^th, 2021; The U.S. Food and Medication Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to care for grown-ups with polycythemia Vera, a blood illness that causes the overproduction of red cells. The abundance cells thicken the blood; easing back blood flow and rising the opportunity of blood clots. Besremi is the main FDA- approved prescription for polycythemia Vera that patients can take no matter what their treatment history, and the primary interferon treatment explicitly approved for polycythemia vera.

FDA Approved isatuximab-irfc for Multiple Myeloma

On March 31^st, 2021; The Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in mix with carfilzomib and dexamethasone, for the treatment of grown-up patients with relapsed or refractory multiple myeloma that have gotten one to three prior lines of treatment. The viability and security of isatuximab-irfc in blend with carfilzomib and dexamethasone was assessed in IKEMA (NCT03275285), a multicenter, global, two-arm, randomized, open- label, phase 3 preliminary in patients with relapsed and/or refractory multiple myeloma who had gotten one to three prior lines of treatment.

AstraZeneca Pharma India to Launch Cancer Drug

On October 15^th, 2020; AstraZeneca Pharma India launched its Acalabrutinib 100 mg capsules, utilized for therapy of different kinds of blood cancers, under the brand name Calquence. The capsules are demonstrated for therapy of patients with mantle cell lymphoma (MCL) who have gotten at least one prior treatment and for therapy of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 53.51 Billion
Base year considered	2021
Forecast Period CAGR %:	10.1%
Market Size Expected in 2029:	USD 104.94 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	AbbVie Inc, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and others
Segments Covered	By Condition, By Therapy, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa.